Indomo pairs established and new dermatology medicines with proprietary delivery hardware to enable fast-acting, self-administered treatments for inflammatory skin conditions. Its first product, the ClearPen, integrates acne therapeutics into a microneedle device designed for at-home use and telehealth support. Led by CEO Rick Bente, the company combines expertise across telehealth, medical devices, and consumer skincare to build an integrated care platform. Indomo is currently advancing the ClearPen through Phase 2 clinical trials while continuing to refine its broader device platform. The company recently secured fresh capital to accelerate these trials and expand its product pipeline. Though still pre-revenue, Indomo positions itself to capture prescription dermatology spend by offering convenient, clinician-directed home treatments. The team aims to leverage telehealth partnerships for distribution and data-driven treatment optimization.

Total raised

$25M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025